REPORT ID 13798

United States Unfractionated Heparin Market Report 2017

Publish Date
22-Nov-17
Pages
98
Format
Electronic (PDF)

In this report, the United States Unfractionated Heparin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Unfractionated Heparin in these regions, from 2012 to 2022 (forecast).

United States Unfractionated Heparin market competition by top manufacturers/players, with Unfractionated Heparin sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    Bayer Healthcare AG
    GlaxoSmithKline
    Boehringer Ingelheim
    Sanofi S.A
    Abbott
    Baxter
    ...

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Oral Drug
    Injection Drug
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Treatment of Venous Thromboembolism
    Complications of Pregnancy
    Cardioversion of Atrial Fibrillation/Flutter

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Unfractionated Heparin Market Report 2017
1 Unfractionated Heparin Overview
    1.1 Product Overview and Scope of Unfractionated Heparin
    1.2 Classification of Unfractionated Heparin by Product Category
        1.2.1 United States Unfractionated Heparin Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Unfractionated Heparin Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Oral Drug
        1.2.4 Injection Drug
    1.3 United States Unfractionated Heparin Market by Application/End Users
        1.3.1 United States Unfractionated Heparin Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Treatment of Venous Thromboembolism
        1.3.3 Complications of Pregnancy
        1.3.4 Cardioversion of Atrial Fibrillation/Flutter
    1.4 United States Unfractionated Heparin Market by Region
        1.4.1 United States Unfractionated Heparin Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Unfractionated Heparin Status and Prospect (2012-2022)
        1.4.3 Southwest Unfractionated Heparin Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Unfractionated Heparin Status and Prospect (2012-2022)
        1.4.5 New England Unfractionated Heparin Status and Prospect (2012-2022)
        1.4.6 The South Unfractionated Heparin Status and Prospect (2012-2022)
        1.4.7 The Midwest Unfractionated Heparin Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Unfractionated Heparin (2012-2022)
        1.5.1 United States Unfractionated Heparin Sales and Growth Rate (2012-2022)
        1.5.2 United States Unfractionated Heparin Revenue and Growth Rate (2012-2022)

2 United States Unfractionated Heparin Market Competition by Players/Suppliers
    2.1 United States Unfractionated Heparin Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Unfractionated Heparin Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Unfractionated Heparin Average Price by Players/Suppliers (2012-2017)
    2.4 United States Unfractionated Heparin Market Competitive Situation and Trends
        2.4.1 United States Unfractionated Heparin Market Concentration Rate
        2.4.2 United States Unfractionated Heparin Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Unfractionated Heparin Manufacturing Base Distribution, Sales Area, Product Type

3 United States Unfractionated Heparin Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Unfractionated Heparin Sales and Market Share by Region (2012-2017)
    3.2 United States Unfractionated Heparin Revenue and Market Share by Region (2012-2017)
    3.3 United States Unfractionated Heparin Price by Region (2012-2017)

4 United States Unfractionated Heparin Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Unfractionated Heparin Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Unfractionated Heparin Revenue and Market Share by Type (2012-2017)
    4.3 United States Unfractionated Heparin Price by Type (2012-2017)
    4.4 United States Unfractionated Heparin Sales Growth Rate by Type (2012-2017)

5 United States Unfractionated Heparin Sales (Volume) by Application (2012-2017)
    5.1 United States Unfractionated Heparin Sales and Market Share by Application (2012-2017)
    5.2 United States Unfractionated Heparin Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Unfractionated Heparin Players/Suppliers Profiles and Sales Data
    6.1 Pfizer
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Unfractionated Heparin Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Pfizer Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Bayer Healthcare AG
        6.2.2 Unfractionated Heparin Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bayer Healthcare AG Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 GlaxoSmithKline
        6.3.2 Unfractionated Heparin Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 GlaxoSmithKline Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Boehringer Ingelheim
        6.4.2 Unfractionated Heparin Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Boehringer Ingelheim Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Sanofi S.A
        6.5.2 Unfractionated Heparin Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Sanofi S.A Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Abbott
        6.6.2 Unfractionated Heparin Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Abbott Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Baxter
        6.7.2 Unfractionated Heparin Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Baxter Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    ...

7 Unfractionated Heparin Manufacturing Cost Analysis
    7.1 Unfractionated Heparin Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Unfractionated Heparin

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Unfractionated Heparin Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Unfractionated Heparin Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Unfractionated Heparin Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Unfractionated Heparin Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Unfractionated Heparin Sales Volume Forecast by Type (2017-2022)
    11.3 United States Unfractionated Heparin Sales Volume Forecast by Application (2017-2022)
    11.4 United States Unfractionated Heparin Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer